David Rodenberg ‐ Clinical Research Associate ‐ Schwabenstieg 7 ‐ 22455 Hamburg Clinical Research Experience Site Coordinator Experience (HOPE – Hemato‐Oncologic Practice Hamburg‐Eppendorf): Year [from–to] [Phase] [Indication] 2011 – 2012 2011 – 2014 2011 – 2014 2011 - 2013 2011 - 2013 2011 - 2014 2012 – 2014 2012 – 2014 2012 – 2012 2012 – 2014 2012 - 2014 2012 - 2014 2011 - 2012 2012 - 2014 2013 – 2014 2013 – 2014 2013 – 2014 2013 – 2014 3 2b 3 2 3 2 2 2 3 3 3 3 2 2/3 2 3 3 2 Adv./met. gastric cancer Adv./met. breast cancer Adv./met. colorectal cancer Adv./met. gastric/esophageal cancer Adv./met. colorectal cancer Adv., resectable gastric/esophageal cancer Resected colorectal cancer Adv./met. breast cancer Adv./met. SCC esophageal cancer GI tumors or breast cancer Gastric cancer Adv./met. breast cancer B-Cell lymphoma Adv./met. gastric/esophageal cancer Adv. stomach cancer Adv./met. breast cancer Adv./met. colorectal cancer Adv./met., unresectable pancreatic cancer Site Monitoring Experience (Novartis Pharma GmbH): Year [from–to] [Phase] [Indication] 2014 - 2015 2014 - 2015 Since 2014 (ongoing) Since 2014 (ongoing) 2014 – 2015 2014 2014 Since 2014 - 2015 Since 2015 (ongoing) Since 2015 (ongoing) 2/3 3 1/2 1 3 NIS 3 1b 1b 2 Adv./met. breast cancer Adv./met. breast cancer Adv./met. NSCLC Advanced solid tumors Tuberous sclerosis complex Tuberous sclerosis complex Prostata carcinoma Selected advanced tumors Adv./met. NSCLC Adv./met. NSCLC David Rodenberg ‐ Clinical Research Associate ‐ Schwabenstieg 7 ‐ 22455 Hamburg Clinical Research Experience Site Monitoring Experience (Quintiles / Roche‐Genentech): Year [from–to] [Phase] [Indication] 2015 - ongoing 3 Urothel-cell carcinomar Stand: 14‐Jan‐2016
© Copyright 2024 ExpyDoc
